ACTIMED THERAPEUTICS

• 74909 - Other professional, scientific and technical activities n.e.c.

Our approach focuses on a class of agents that may have multiple effects on the fundamental biology of cachexia to reduce catabolism (weight loss), increase and maintain anabolism (weight gain, particularly muscle mass gain), decrease fatigue, and stimulate appetite... Our lead product, S-pindolol benzoate (ACM-001.1) is a new salt of S-pindolol in clinical development for cancer-related cachexia. S-pindolol has demonstrated promising results in a Phase 2a, proof of concept trial and Phase 2b/3 clinical development programme is now planned. Our vision is to develop the first globally approved treatment for cancer cachexia and to develop a product portfolio to bring much needed innovation to the treatment of cachexia, amyotrophic lateral sclerosis and other muscle wasting conditions... We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives,..

Also known as: ACTIMED THERAPEUTICS LIMITED, ACTIMED THERAPEUTICS LTD

Registration numbers: 10519588 (CH)

VAT numbers: 284062307

Primary location: Ascot United Kingdom